MedTrace Logo

Safety and Efficacy of CDB-2914 for Emergency Contraception

NCT00411684 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1623

Last updated 2021-09-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.

Conditions

  • Emergency Contraception

Interventions

DRUG

CDB-2914

Sponsors & Collaborators

  • HRA Pharma

    lead INDUSTRY

Principal Investigators

  • Paul Fine, MD · Planned Parenthood of Houston and Southeast Texas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-04-08
Completion
2009-06-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00411684 on ClinicalTrials.gov